Abstract
Background: Omalizumab is prescribed as a step-up therapy for patients with moderate to severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long acting beta agonists. However, hypersensitivity reactions may lead to its discontinuation and subsequent worsening or loss of asthma control. No successful desensitization protocols to omalizumab have been previously reported.
Objective: We aimed to determine the efficacy and safety of a novel one-day outpatient omalizumab desensitization protocol for patients with hypersensitivity reactions to omalizumab.
Methods: We retrospectively assessed the efficacy of omalizumab desensitization protocol performed in a university allergy-immunology clinic from July 2009 to July 2010.
Results: We successfully desensitized 3 patients with moderate-severe asthma to omalizumab. After desensitization all patients had improvement in asthma control and were able to discontinue or decrease chronic systemic steroid therapy.
Conclusions: This novel outpatient omalizumab desensitization protocol was a safe and effective approach for the treatment of omalizumab hypersensitivity in patients with moderate to severe allergic asthma who required omalizumab therapy.
Keywords: Asthma, omalizumab, hypersensitivity, desensitization, IgG1 monoclonal antibody, LABA therapy
Current Drug Safety
Title: Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab
Volume: 6 Issue: 5
Author(s): Gregory Owens and Andrej Petrov
Affiliation:
Keywords: Asthma, omalizumab, hypersensitivity, desensitization, IgG1 monoclonal antibody, LABA therapy
Abstract: Background: Omalizumab is prescribed as a step-up therapy for patients with moderate to severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long acting beta agonists. However, hypersensitivity reactions may lead to its discontinuation and subsequent worsening or loss of asthma control. No successful desensitization protocols to omalizumab have been previously reported.
Objective: We aimed to determine the efficacy and safety of a novel one-day outpatient omalizumab desensitization protocol for patients with hypersensitivity reactions to omalizumab.
Methods: We retrospectively assessed the efficacy of omalizumab desensitization protocol performed in a university allergy-immunology clinic from July 2009 to July 2010.
Results: We successfully desensitized 3 patients with moderate-severe asthma to omalizumab. After desensitization all patients had improvement in asthma control and were able to discontinue or decrease chronic systemic steroid therapy.
Conclusions: This novel outpatient omalizumab desensitization protocol was a safe and effective approach for the treatment of omalizumab hypersensitivity in patients with moderate to severe allergic asthma who required omalizumab therapy.
Export Options
About this article
Cite this article as:
Owens Gregory and Petrov Andrej, Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab, Current Drug Safety 2011; 6 (5) . https://dx.doi.org/10.2174/157488611798918692
DOI https://dx.doi.org/10.2174/157488611798918692 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preclinical Models of Graves’ Disease and Associated Secondary Complications
Current Pharmaceutical Design Advances in Encoding of Colloids for Combinatorial Libraries: Applications in Genomics, Proteomics and Drug Discovery
Current Pharmaceutical Biotechnology Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Factors Influencing Individual Variability in the Therapeutic Response to Corticosteroids in Asthma
Current Respiratory Medicine Reviews Perception or Reality of Body Weight: Which Matters the Most to Adolescents’ Emotional Well-being?
Current Psychiatry Reviews Structure and Function of Poly(ADP-ribose) Polymerase-1: Role in Oxidative Stress-Related Pathologies
Current Vascular Pharmacology Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology The Dual Role of Interleukin-25 in the Control of Immune-Mediated Pathologies
Current Molecular Medicine Blocking Leukocyte Rolling: Does it have a Role in Disease Prevention?
Vascular Disease Prevention (Discontinued) Spray-Dried Polymeric Nanoparticles for Pharmaceutics: A Review of Patents
Recent Patents on Drug Delivery & Formulation Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Liverworts-Potential Source of Medicinal Compounds
Current Pharmaceutical Design Anti-Inflammatory Trends of 1, 3-Diphenyl-2-propen-1-one Derivatives
Mini-Reviews in Medicinal Chemistry Non-Injection Routes for Allergen Immunotherapy: Focus on Sublingual Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Resistin-Like Molecule-α Causes Lung Injury in Rats with Acute Pancreatitis by Activating the PI-3K/Akt-NF-κB Pathway and Promoting Inflammatory Cytokine Release
Current Molecular Medicine RNA Interference: New Therapeutics in Allergic Diseases
Current Gene Therapy Editorial [Hot Topic: Comparative Biochemistry of Molecular Targets for Drug and Pesticides: N-Acetyl-D-glucosamine and Acetylcholine Related Enzymes (Guest Editor: Qing Yang )]
Current Drug Targets Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology Novel Biologics for the Treatment of Pediatric Severe Asthma
Current Respiratory Medicine Reviews The Pharmacogenomics of Asthma Beyond its Endotypes
Current Drug Metabolism